Oryzon Genomics S.A. (0RDB.L)
EUR 2.76
(-1.43%)
EUR 2.76
(-1.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.02 Million USD | 14.67% |
| 2022 | -5.88 Million USD | 26.26% |
| 2021 | -7.98 Million USD | -52.29% |
| 2020 | -5.24 Million USD | -21.86% |
| 2019 | -4.3 Million USD | -16.01% |
| 2018 | -3.7 Million USD | 34.68% |
| 2017 | -5.67 Million USD | -8.94% |
| 2016 | -5.2 Million USD | -565.27% |
| 2015 | -783.13 Thousand USD | -106.55% |
| 2014 | 11.94 Million USD | 491.11% |
| 2013 | -3.05 Million USD | -400.51% |
| 2012 | -610.37 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 922.61 Thousand USD | 126.37% |
| 2024 Q1 | -3.49 Million USD | 30.77% |
| 2023 Q2 | 2.89 Million USD | 151.7% |
| 2023 FY | -20.87 Million USD | -254.71% |
| 2023 Q1 | -5.59 Million USD | -160.13% |
| 2023 Q4 | -5.05 Million USD | -12.44% |
| 2023 Q3 | -4.49 Million USD | -255.4% |
| 2022 Q2 | 2.71 Million USD | 148.76% |
| 2022 Q1 | -5.57 Million USD | -184.24% |
| 2022 FY | -5.88 Million USD | 26.26% |
| 2022 Q4 | 9.3 Million USD | 288.61% |
| 2022 Q3 | -4.93 Million USD | -281.6% |
| 2021 Q3 | -5.05 Million USD | -407.23% |
| 2021 Q2 | 1.64 Million USD | 129.47% |
| 2021 FY | -7.98 Million USD | -52.29% |
| 2021 Q4 | 6.61 Million USD | 230.91% |
| 2021 Q1 | -5.58 Million USD | -350.46% |
| 2020 Q1 | -1.04 Million USD | -37.65% |
| 2020 FY | -5.24 Million USD | -21.86% |
| 2020 Q4 | -1.23 Million USD | -18.43% |
| 2020 Q3 | -1.04 Million USD | 11.56% |
| 2020 Q2 | -1.18 Million USD | -12.89% |
| 2019 FY | -4.3 Million USD | -16.01% |
| 2019 Q4 | -761.19 Thousand USD | 16.83% |
| 2019 Q2 | -1.34 Million USD | -26.74% |
| 2019 Q1 | -1.05 Million USD | -44.73% |
| 2019 Q3 | -915.19 Thousand USD | 31.85% |
| 2018 Q3 | -878.46 Thousand USD | 14.87% |
| 2018 Q4 | -732.11 Thousand USD | 16.66% |
| 2018 FY | -3.7 Million USD | 34.68% |
| 2018 Q2 | -1.03 Million USD | -23.56% |
| 2018 Q1 | -835.13 Thousand USD | 42.94% |
| 2017 Q2 | -1.46 Million USD | -26.02% |
| 2017 Q1 | -1.16 Million USD | 11.25% |
| 2017 Q4 | -1.46 Million USD | -36.9% |
| 2017 Q3 | -1.06 Million USD | 26.94% |
| 2017 FY | -5.67 Million USD | -8.94% |
| 2016 Q3 | -1.17 Million USD | 36.69% |
| 2016 FY | -5.2 Million USD | -565.27% |
| 2016 Q4 | -1.3 Million USD | -11.29% |
| 2016 Q2 | -1.85 Million USD | -116.07% |
| 2016 Q1 | -859.36 Thousand USD | -24.34% |
| 2015 Q4 | -691.11 Thousand USD | -104.37% |
| 2015 Q1 | -745.81 Thousand USD | 3.69% |
| 2015 Q2 | 1.11 Million USD | 249.24% |
| 2015 FY | -783.13 Thousand USD | -106.55% |
| 2015 Q3 | -338.17 Thousand USD | -130.38% |
| 2014 Q4 | -774.37 Thousand USD | 4.09% |
| 2014 Q2 | 5.57 Million USD | -0.0% |
| 2014 Q3 | -807.4 Thousand USD | -114.48% |
| 2014 FY | 11.94 Million USD | 491.11% |
| 2014 Q1 | 5.57 Million USD | 0.0% |
| 2013 FY | -3.05 Million USD | -400.51% |
| 2012 FY | -610.37 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Boiron SA | 42.29 Million EUR | 111.876% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 102.28% |
| Vetoquinol SA | 74.26 Million EUR | 106.763% |
| Valneva SE | -82.08 Million EUR | 93.882% |
| AB Science S.A. | -13.42 Million EUR | 62.601% |
| Nanobiotix S.A. | -26.77 Million EUR | 81.245% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 78.773% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 82.584% |
| BioSenic S.A. | -7.04 Million EUR | 28.661% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 96.057% |
| Formycon AG | -369 Thousand EUR | -1261.055% |